A study found that the systemic immune-inflammation index (SII) is a robust prognostic tool for diffuse large B cell lymphoma (DLBCL).
To conduct this study, researchers retrospectively analyzed 224 patients with DLBCL between August 2005 and October 2018. They used Kaplan-Meier analysis and Cox proportional hazard models to assess the prognostic value of SII.
Following analysis, the results showed that SII had the highest area under the ROC curve (AUC), and was accurate as a prognostic factor. Patients with higher SII tended to have higher level of LDH, more advanced stage disease, and higher IPI scores compared with the low SII group. In univariate analyses, SII was observed as a strong prognostic indicator of progression-free survival and overall survival. Moreover, the researchers noted, only SII, older age, HBSAg-positive and IPI were the independent prognostic factors for patients in multivariate analysis.
“SII was a powerful tool for predicting outcome in patients with DLBCL. It might assist the separation of high-risk patients among patients with the same IPI,” the researchers concluded.
Keywords: diffuse large B-cell lymphoma, lymphocyte, neutrophil, nomogram, platelet, prognosis, systemic immune-inflammation index